See the Glossary for more terms.
NIAID welcomes our new Council members for 2016: Raul Andino, Aftab A. Ansari, Sally L. Hodder, Karen E. Nelson, and Cara Wilson.
Aftab A. Ansari, Ph.D., is professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. He is a basic immunologist with a broad background in transplantation immunology and infectious disease research, which includes serving as scientific director of the U.S. Navy overseas research laboratories in Cairo, Egypt, and Jakarta, Indonesia. Dr. Ansari’s current research focus is on defining methods and strategies to reduce and/or prevent gastrointestinal pathology in the SIV-infected nonhuman primate model of HIV infection to help facilitate generating effective antiviral immune responses. (October 31, 2019)
Amanda Castel, M.D., M.P.H., is associate professor of epidemiology and pediatrics at The George Washington University. She is a medical epidemiologist with training in preventive medicine and applied public health epidemiology. One of Dr. Castel’s research areas is characterizing outcomes along the HIV-care continuum through the use of public health surveillance and clinical data. She also develops interventions to maximize outcomes along the continuum, including routine testing expansion, enhancing retention in care and medication adherence, and reducing community viral load. (October 31, 2018)
Cara Wilson, M.D., is professor of medicine (infectious diseases subspecialty) and immunology at the University of Colorado, Denver (UCD). She is a physician-scientist whose laboratory studies the human immune response to HIV-1 infection and the factors that drive HIV-1 pathogenesis and inflammation in intestinal mucosal tissue, especially microbiome-related factors. Dr. Wilson is a member of the UCD Mucosal Inflammation Program, which provides a supportive infrastructure for studies of intestinal inflammation. She also has extensive experience in designing and implementing clinical trials focused on HIV-associated immune activation and immune-based therapies through her longstanding involvement in the AIDS Clinical Trials Group. (October 31, 2019)
Stephen J. Galli, M.D., is Mary Hewitt Loveless, M.D., Professor; chair and professor of pathology; and professor of microbiology and immunology at Stanford University. He investigates the roles of mast cells and basophils in health and disease, including in host defense and allergic disorders such as food allergy and asthma. Dr. Galli has been a member or chair of NIH study sections and co-chaired an NIAID Food Allergy Research Expert Panel. He belongs to the Collegium Internationale Allergologicum where he served as president from 2010 to 2014, Institute of Medicine of the U.S. National Academy of Sciences, and Accademia Nazionale dei Lincei. (October 31, 2018)
Gurjit Khurana Hershey, M.D., Ph.D., is Kindervelt Endowed Chair in Asthma Research and professor of pediatrics at Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine. She is also director of the Medical Scientist Training Program at the University of Cincinnati and co-director of the Office of Pediatric Clinical Fellowships at Cincinnati Children's Hospital Medical Center. Dr. Khurana Hershey’s research focuses on the overall goal of improving the health of children with asthma. Her laboratory integrates clinical, epidemiologic, translational, and basic research approaches to identify and delineate the mechanistic basis of genetic and environmental factors that contribute to the development, progression, and persistence of asthma. (October 31, 2018)
Arlene Sharpe, M.D., Ph.D., is George Fabyan Professor of Comparative Pathology at Harvard Medical School. She is also head of the Division of Immunology in the Department of Microbiology and Immunobiology and co-director of the Harvard Institute of Translational lmmunology. Dr. Sharpe is a leader in the field of costimulation. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating pathogenic and protective immune responses needed for inducing and maintaining T cell tolerance and effective antimicrobial and antitumor immunity. Her laboratory is also involved in studies aimed at translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases, chronic viral infections, and tumor immunotherapy. (October 31, 2017)
Raul Andino, Ph.D., is professor of microbiology and immunology at the University of California, San Francisco, where he specializes in RNA viruses, with a focus on molecular biology, immunology, and evolutionary biology. His research includes mechanisms of replication, antiviral RNAi, and adaptation. Dr. Andino is interested in the evolution of the immune system and the role of virus population diversity in pathogenesis. Understanding the rules that control host and virus evolution has important implications for vaccine development and antivirals. He has served on several national advisory panels and is currently chair of the NIAID Systems Biology Program (SysBio) Steering Committee. (October 31, 2019)
Norman W. Baylor, Ph.D., is president and CEO of Biologics Consulting Group, Inc. Previously, Dr. Baylor was the director of the Office of Vaccines Research and Review in the Food and Drug Administration’s Center for Biologics Evaluation and Research. He evaluated and facilitated the development and licensure of numerous vaccines. Dr. Baylor served as FDA’s liaison to CDC’s Advisory Committee on Immunization Practices, U.S. Department of Health and Human Services National Vaccine Advisory Committee, and the Advisory Commission on Childhood Vaccines. He also served as an expert advisor to the World Health Organization on several global vaccine initiatives. (October 31, 2016)
Larry S. Schlesinger, M.D., is Samuel Saslaw Professor and chair of the Department of Microbial Infection and Immunity in the College of Medicine at The Ohio State University. He also serves as director of the OSU Center for Microbial Interface Biology and Medical Scientist Training Program. Dr. Schlesinger is a cellular immunologist whose studies focus on the pathogenesis of tuberculosis and other airborne infections caused by intracellular pathogens that subvert lung immune mechanisms. He has been a member or chair of several study sections at NIH and other federal and private agencies. (October 31, 2017)
For more information, see the Advisory Council portal.
Last Updated January 22, 2016
Last Reviewed January 22, 2016